Abstract
Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Current Cancer Therapy Reviews
Title: New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Volume: 6 Issue: 3
Author(s): Yuexing Zhang and Anne W. Hamburger
Affiliation:
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Abstract: Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Export Options
About this article
Cite this article as:
Zhang Yuexing and W. Hamburger Anne, New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698205
DOI https://dx.doi.org/10.2174/157339410791698205 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxicity and Cell Death Mechanisms Induced by a Novel Bisnaphthalimidopropyl Derivative against the NCI-H460 non-small Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Effect of Liposomes with Different Double Arms Polyethyleneglycol on Hepatic Metastasis Model Mice and Evaluation Using a Fluorescent Imaging Device
Current Drug Delivery Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine CD147 Promotes Melanoma Progression Through Hypoxia-Induced MMP2 Activation
Current Molecular Medicine Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Hesperetin Liposomes for Cancer Therapy
Current Drug Delivery <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry mPEG-PLA Micelle for Delivery of Effective Parts of Andrographis Paniculata
Current Drug Delivery Recent Advances in PET Imaging for Skeletal Surgery Applications
Recent Patents on Medical Imaging IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Biomarkers for Early Detection of Liver Cancer: Focus on Clinical Evaluation
Protein & Peptide Letters The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
Current Medicinal Chemistry Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued)